



ABIVAX to report first-half 2015 results

Paris, 1st September 2015 – ABIVAX (Euronext Paris: ABVX), a Paris-based leading clinical stage biotech company developing and commercializing anti-viral compounds and human vaccines, today announced that it will publish its financial results for the first half of 2015 on **September 29, 2015**, post-market. The results will also be made available on the company's website, www.abivax.com.

About ABIVAX

ABIVAX is an advanced clinical stage biotech company focused on becoming a global leader in the discovery, development and commercialization of anti-viral compounds and human vaccines to treat some of the world's most life-threatening infectious diseases, including HIV/AIDS and chronic Hepatitis B.

ABIVAX has two compounds in clinical stage research: ABX464 a novel small molecule against HIV with a number of important potential competitive advantages, and ABX203, a therapeutic vaccine candidate that could be a cure for chronic hepatitis B. The broader ABIVAX portfolio includes additional anti-viral compounds and vaccines that may enter the clinical stage in the coming 18 months.

ABX464 has been developed using ABIVAX' anti-viral platform that allows the Company to address a broad range of viral targets involved in the production and management of viral RNA within the host cell. ABIVAX also has access to a number of cutting edge technologies including complex molecular protein/RNA-pro interactions to discover and develop proprietary breakthrough therapies to help patients' clear important pathogenic viruses.

Headquartered in Paris, France, ABIVAX conducts its research and development in Évry (France) and Montpellier (France). In addition, ABIVAX benefits from long term partnerships with the Cuban Center for Genetic Engineering and Biotechnology (Havana, Cuba), The Finlay Institute (Havana, Cuba), the Molecular Genetics Institute of Montpellier (CNRS-Université de Montpellier, France), the Curie Institute (Paris, France), the Scripps Research Institute (La Jolla, CA, USA), the University of Chicago (Chicago, IL, USA), Brigham Young University (Provo, UT, USA), Institut Curie (Paris, France) and the Institut Pasteur (Paris, France). ABIVAX intends to pursue further business development opportunities to access commercial products as part of its overall corporate strategy.

ABIVAX was founded by Dr. Philippe Pouletty, M.D. , managing partner at Truffle Capital, the cornerstone investor in ABIVAX since its creation.

For more information, please visit the company's website: www.ABIVAX.com

Contacts

ABIVAX

Prof. Hartmut J. Ehrlich CEO

Press Relations

Citigate Dewe Rogerson

Lucie Larguier (Paris)

David Dible (London)

[lucie.larguier@citigate.fr](mailto: lucie.larguier@citigate.fr)/[david.dible@citigatedr.co.uk](mailto: david.dible@citigatedr.co.uk)

+33 1 53 32 84 75 / +44 20 7282 2949